{"id":745408,"date":"2016-03-08T08:00:00","date_gmt":"2016-03-08T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\/"},"modified":"2025-11-07T01:25:57","modified_gmt":"2025-11-07T06:25:57","slug":"sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\/","title":{"rendered":"Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies"},"content":{"rendered":"<p>\n      Sanofi Pasteur and Merck, known as MSD outside the United States and<br \/>\n      Canada, today announced their intent to end their joint vaccines<br \/>\n      operations in Europe. Upon concluding their joint venture, both<br \/>\n      companies plan to integrate their respective European vaccine businesses<br \/>\n      into their operations, independently manage their product portfolios and<br \/>\n      pursue their own distinct growth strategies in Europe.\n    <\/p>\n<p>\n      The joint venture Sanofi Pasteur MSD, owned on a 50\/50 basis by Sanofi<br \/>\n      Pasteur and MSD, was created in 1994 to develop and commercialize<br \/>\n      vaccines originating from both companies\u2019 pipelines to improve and<br \/>\n      promote public health in 19 European countries. Over the past twenty<br \/>\n      years, Sanofi Pasteur MSD has launched numerous innovative vaccines<br \/>\n      originating from Sanofi Pasteur and MSD\u2019s development pipelines,<br \/>\n      addressing key unmet medical needs and helping to protect millions of<br \/>\n      lives.\n    <\/p>\n<p>\n      Sanofi Pasteur and MSD jointly issued the following statement: \u201cWe are<br \/>\n      proud of Sanofi Pasteur MSD\u2019s successful 20-year history. Our joint<br \/>\n      venture has achieved considerable success over the past two decades from<br \/>\n      a public health and commercial perspective. After carefully considering<br \/>\n      our individual strategic priorities, alongside the economic and<br \/>\n      regulatory environments for vaccine operations in the European Union, we<br \/>\n      have mutually agreed that it is in our best interests to manage our<br \/>\n      vaccine product portfolios independently. We believe that focusing our<br \/>\n      efforts on opportunities unique to our respective companies will better<br \/>\n      position us to drive growth, execute in a more efficient manner and<br \/>\n      optimize vaccine coverage. By bringing vaccines more rapidly to market,<br \/>\n      both companies would deliver greater value to all stakeholders.\u201d\n    <\/p>\n<p>\n      Sanofi Pasteur and MSD will ensure that any impact on employees as a<br \/>\n      result of the proposed changes to the business model will be managed<br \/>\n      responsibly. We are also focused on a smooth and orderly transition<br \/>\n      while achieving our public healthcare goals and upholding our<br \/>\n      commitments to our customers and business partners.\n    <\/p>\n<p>\n      Sanofi Pasteur and MSD expect the project to be completed by the end of<br \/>\n      2016, subject to local labor laws and regulations and regulatory<br \/>\n      approvals.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51295292&amp;newsitemid=20160308005897&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=f7254213c93f901c591cb0880edeb7b3\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51295292&amp;newsitemid=20160308005897&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=fc343308c1e7d654d013fd066811319b\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51295292&amp;newsitemid=20160308005897&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=d770b3415b86501239b110f80f68ac0c\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51295292&amp;newsitemid=20160308005897&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=cb90af193c71175b38cf684a59301df3\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51295292&amp;newsitemid=20160308005897&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=9ef75425c40fe077c12a83204ec60547\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. If underlying assumptions prove<br \/>\n      inaccurate or risks or uncertainties materialize, actual results may<br \/>\n      differ materially from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51295292&amp;newsitemid=20160308005897&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=3c9860b0ef0832027e00e02597634beb\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>About Sanofi Pasteur MSD<\/b>\n    <\/p>\n<p>\n      Sanofi Pasteur MSD is a European joint venture formed between Sanofi<br \/>\n      Pasteur (the vaccine division of Sanofi) and Merck (known as MSD outside<br \/>\n      the United States and Canada). Sanofi Pasteur MSD makes use of the<br \/>\n      combined expertise resulting from Sanofi Pasteur and Merck\u2019s research to<br \/>\n      focus on the development of new vaccines in Europe in order to produce<br \/>\n      the most effective, most acceptable and better tolerated vaccines. Sales<br \/>\n      of Sanofi Pasteur MSD were \u20ac824 million in 2015. For more information<br \/>\n      visit: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.spmsd.com&amp;esheet=51295292&amp;newsitemid=20160308005897&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.spmsd.com&amp;index=7&amp;md5=ca967760c96a243f06d422507b0c0a66\" rel=\"nofollow\">http:\/\/www.spmsd.com<\/a>\n    <\/p>\n<p>\n      <b>About Sanofi<\/b>\n    <\/p>\n<p>\n      Sanofi, a global healthcare leader, discovers, develops and distributes<br \/>\n      therapeutic solutions focused on patients\u2019 needs. Sanofi has core<br \/>\n      strengths in diabetes solutions, human vaccines, innovative drugs,<br \/>\n      consumer healthcare, emerging markets, animal health and Genzyme. Sanofi<br \/>\n      is listed in Paris (EURONEXT:<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fen.sanofi.com%2Finvestors%2Fshare%2Fstock_chart%2Fstock_chart.aspx&amp;esheet=51295292&amp;newsitemid=20160308005897&amp;lan=en-US&amp;anchor=SAN&amp;index=8&amp;md5=7d8601c7dbad07d128230d49c5de1988\" rel=\"nofollow\">SAN<\/a>)<br \/>\n      and in New York (NYSE:<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fen.sanofi.com%2Finvestors%2Fshare%2Fstock_chart%2Fstock_chart.aspx&amp;esheet=51295292&amp;newsitemid=20160308005897&amp;lan=en-US&amp;anchor=SNY&amp;index=9&amp;md5=04406fb96f0e6a50d53471e78d406df1\" rel=\"nofollow\">SNY<\/a>).\n    <\/p>\n<p>\n      Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1<br \/>\n      billion doses of vaccine each year, making it possible to immunize more<br \/>\n      than 500 million people across the globe. A world leader in the vaccine<br \/>\n      industry, Sanofi Pasteur offers a broad range of vaccines protecting<br \/>\n      against 20 infectious diseases. The company&#8217;s heritage, to create<br \/>\n      vaccines that protect life, dates back more than a century. Sanofi<br \/>\n      Pasteur is the largest company entirely dedicated to vaccines. Every<br \/>\n      day, the company invests more than EUR 1 million in research and<br \/>\n      development. For more information, please visit: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sanofipasteur.com&amp;esheet=51295292&amp;newsitemid=20160308005897&amp;lan=en-US&amp;anchor=www.sanofipasteur.com&amp;index=10&amp;md5=7ab56ef33f64571c4940c130ef956d20\" rel=\"nofollow\">www.sanofipasteur.com<\/a><br \/>\n      or <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sanofipasteur.us&amp;esheet=51295292&amp;newsitemid=20160308005897&amp;lan=en-US&amp;anchor=www.sanofipasteur.us&amp;index=11&amp;md5=b8bb935e6455938dc73adbbfa4121a36\" rel=\"nofollow\">www.sanofipasteur.us<\/a>\n    <\/p>\n<p>\n      <b>Forward Looking Statements of Sanofi<\/b>\n    <\/p>\n<p>\n      This press release contains forward-looking statements as defined in the<br \/>\n      Private Securities Litigation Reform Act of 1995, as amended.<br \/>\n      Forward-looking statements are statements that are not historical facts.<br \/>\n      These statements include projections and estimates and their underlying<br \/>\n      assumptions, statements regarding plans, objectives, intentions and<br \/>\n      expectations with respect to future financial results, events,<br \/>\n      operations, services, product development and potential, and statements<br \/>\n      regarding future performance. Forward-looking statements are generally<br \/>\n      identified by the words \u201cexpects\u201d, \u201canticipates\u201d, \u201cbelieves\u201d, \u201cintends\u201d,<br \/>\n      \u201cestimates\u201d, \u201cplans\u201d and similar expressions. Although Sanofi\u2019s<br \/>\n      management believes that the expectations reflected in such<br \/>\n      forward-looking statements are reasonable, investors are cautioned that<br \/>\n      forward-looking information and statements are subject to various risks<br \/>\n      and uncertainties, many of which are difficult to predict and generally<br \/>\n      beyond the control of Sanofi, that could cause actual results and<br \/>\n      developments to differ materially from those expressed in, or implied or<br \/>\n      projected by, the forward-looking information and statements. These<br \/>\n      risks and uncertainties include among other things, the uncertainties<br \/>\n      inherent in research and development, future clinical data and analysis,<br \/>\n      including post marketing, decisions by regulatory authorities, such as<br \/>\n      the FDA or the EMA, regarding whether and when to approve any drug,<br \/>\n      device or biological application that may be filed for any such product<br \/>\n      candidates as well as their decisions regarding labelling and other<br \/>\n      matters that could affect the availability or commercial potential of<br \/>\n      such product candidates, the absence of guarantee that the product<br \/>\n      candidates if approved will be commercially successful, the future<br \/>\n      approval and commercial success of therapeutic alternatives, the Group\u2019s<br \/>\n      ability to benefit from external growth opportunities, trends in<br \/>\n      exchange rates and prevailing interest rates, the impact of cost<br \/>\n      containment initiatives and subsequent changes thereto, the average<br \/>\n      number of shares outstanding as well as those discussed or identified in<br \/>\n      the public filings with the SEC and the AMF made by Sanofi, including<br \/>\n      those listed under \u201cRisk Factors\u201d and \u201cCautionary Statement Regarding<br \/>\n      Forward-Looking Statements\u201d in Sanofi\u2019s annual report on Form 20-F for<br \/>\n      the year ended December 31, 2014. Other than as required by applicable<br \/>\n      law, Sanofi does not undertake any obligation to update or revise any<br \/>\n      forward-looking information or statements.\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160308005897r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Lainie Keller, 908-236-5036<br \/>or<br \/>Investor:<br \/>Justin        Holko, 908-740-1879<br \/>or<br \/>Sanofi Pasteur<br \/>Media:<br \/>Alain        Bernal, +33 4 37 37 50 38<br \/>or<br \/>Investor:<br \/>S\u00e9bastien Martel,        +33 1 53 77 45 45     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi Pasteur and Merck, known as MSD outside the United States and Canada, today announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their product portfolios and pursue their own distinct growth strategies in Europe. The joint venture Sanofi Pasteur MSD, owned on a 50\/50 basis by Sanofi Pasteur and MSD, was created in 1994 to develop and commercialize vaccines originating from both companies\u2019 pipelines to improve and promote public health in 19 European countries. Over the past twenty years, Sanofi Pasteur MSD has launched numerous innovative vaccines originating from Sanofi Pasteur and MSD\u2019s development pipelines, addressing key unmet medical needs and helping to protect millions of lives. Sanofi Pasteur and MSD jointly issued the following statement: \u201cWe are proud of Sanofi Pasteur MSD\u2019s successful<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,57],"class_list":["post-745408","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-vaccine-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Sanofi Pasteur and Merck, known as MSD outside the United States and Canada, today announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their product portfolios and pursue their own distinct growth strategies in Europe. The joint venture Sanofi Pasteur MSD, owned on a 50\/50 basis by Sanofi Pasteur and MSD, was created in 1994 to develop and commercialize vaccines originating from both companies\u2019 pipelines to improve and promote public health in 19 European countries. Over the past twenty years, Sanofi Pasteur MSD has launched numerous innovative vaccines originating from Sanofi Pasteur and MSD\u2019s development pipelines, addressing key unmet medical needs and helping to protect millions of lives. Sanofi Pasteur and MSD jointly issued the following statement: \u201cWe are proud of Sanofi Pasteur MSD\u2019s successful\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\\\/\",\"name\":\"Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-03-08T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\/","og_locale":"en_US","og_type":"article","og_title":"Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies - Merck.com","og_description":"Sanofi Pasteur and Merck, known as MSD outside the United States and Canada, today announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their product portfolios and pursue their own distinct growth strategies in Europe. The joint venture Sanofi Pasteur MSD, owned on a 50\/50 basis by Sanofi Pasteur and MSD, was created in 1994 to develop and commercialize vaccines originating from both companies\u2019 pipelines to improve and promote public health in 19 European countries. Over the past twenty years, Sanofi Pasteur MSD has launched numerous innovative vaccines originating from Sanofi Pasteur and MSD\u2019s development pipelines, addressing key unmet medical needs and helping to protect millions of lives. Sanofi Pasteur and MSD jointly issued the following statement: \u201cWe are proud of Sanofi Pasteur MSD\u2019s successful","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:57+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\/","name":"Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-03-08T08:00:00+00:00","dateModified":"2025-11-07T06:25:57+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sanofi-pasteur-and-merck-known-as-msd-outside-the-united-states-and-canada-announce-intent-to-end-joint-vaccines-operations-in-europe-sanofi-pasteur-msd-to-pursue-their-own-distinct-growth-strateg\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"8cd31a71-b57d-4eee-8ddc-226c11820fbe","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745408\/revisions"}],"predecessor-version":[{"id":3674799,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745408\/revisions\/3674799"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745408"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}